stockrowAlkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
- Revenue
- +21.8%
- EPS
- −80.6%
- Free cash flow
- +6.78%
Quarter to September 2026, against a year earlier
Follow ALKS
Alert me
Alkermes plc (ALKS) Net income
Alkermes plc's net income for fiscal 2025 was $241.7M, down 34.2% from $367.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$351.0K. Over the past ten years it has ranged from −$227.2M (fiscal 2015) to $367.1M (fiscal 2024); the current reading is higher than 82% of that period. Alkermes plc ranks 27th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $241.7M | (34.16%) |
| FY2024 | $367.1M | 3.18% |
| FY2023 | $355.8M | — |
| FY2022 | −$158.3M | — |
| FY2021 | −$48.2M | — |
| FY2020 | −$110.9M | — |
| FY2019 | −$196.6M | — |
| FY2018 | −$139.3M | — |
| FY2017 | −$157.9M | — |
| FY2016 | −$208.4M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $16.3M | 3,150.90% |
| Jun 2026 | $501.0K | — |
| Mar 2026 | −$66.5M | — |
| Dec 2025 | $49.3M | (40.38%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. compare | $450.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| LNTH Lantheus Holdings, Inc. compare | $269.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $209.5M |
| LQDA Liquidia Corporation compare | $138.6M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $109.6M |
| ALKS Alkermes plc | −$351.0K |
| HIMS Hims & Hers Health, Inc. compare | −$142.0M |
| ELAN Elanco Animal Health Incorporated compare | −$199.0M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ALKS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement